Isosorbide DinitrateThird Party Manufacturing in India

Isosorbide Dinitrate acts as a prodrug that is denitrated in the body to release nitric oxide, a potent endogenous vasodilator that activates soluble guanylyl cyclase in vascular smooth muscle cells. The nitric oxide binds to the haem moiety of guanylyl cyclase, causing a conformational change that activates the enzyme and increases the conversion of guanosine triphosphate to cyclic guanosine monophosphate. Elevated intracellular cGMP levels activate cGMP-dependent protein kinase, which phosphorylates multiple target proteins including myosin light chain kinase, leading to dephosphorylation of the myosin light chain and relaxation of vascular smooth muscle. This vasodilatory effect is most pronounced in the venous capacitance vessels, where it reduces venous return to the heart, decreasing left ventricular end-diastolic volume and pressure, which in turn reduces myocardial wall tension and oxygen demand. At higher doses, Isosorbide Dinitrate also dilates coronary arteries and arterioles, improving coronary blood flow and oxygen supply to ischaemic myocardium. The drug also inhibits platelet aggregation through cGMP-mediated mechanisms, which may contribute to its therapeutic effect in acute coronary syndromes. A unique feature of Isosorbide Dinitrate compared to other nitrates is its first-pass hepatic metabolism, which produces the active metabolite isosorbide-5-mononitrate that has a longer half-life and contributes significantly to the sustained anti-anginal effect. The drug is available in immediate-release formulations for acute angina relief and in sustained-release formulations for long-term prophylaxis.

Isosorbide Dinitrate is a widely prescribed nitrate vasodilator used primarily for the prevention and treatment of angina pectoris resulting from coronary artery disease. It belongs to the class of organic nitrates and is available in both short-acting and long-acting formulations to manage different phases of ischaemic heart disease. The drug is available in 5mg and 10mg strengths, providing dosing flexibility for both acute symptom control and chronic prophylaxis.

Therapeutic Uses

• Chronic Stable Angina: Isosorbide Dinitrate is indicated for the long-term prophylactic management of chronic stable angina pectoris, reducing the frequency and severity of anginal episodes and improving exercise tolerance in patients with coronary artery disease.
• Acute Angina Pectoris: In immediate-release formulations, the drug provides rapid relief of acute anginal episodes by reducing preload and afterload, thereby decreasing myocardial oxygen demand.
• Congestive Heart Failure: Isosorbide Dinitrate is used as adjunctive therapy in the management of congestive heart failure, particularly in combination with hydralazine, where it reduces preload and afterload to improve cardiac output and symptoms.
• Silent Myocardial Ischaemia: The drug is effective in reducing the frequency and duration of asymptomatic ischaemic episodes detected by ambulatory ECG monitoring in patients with documented coronary artery disease.

Why Manufacturers Choose Isosorbide Dinitrate

Isosorbide Dinitrate is a well-established cardiac molecule with consistent demand from cardiology practices, hospital formularies, and government procurement programmes across India and export markets. Indian manufacturers produce both the standard 5mg and 10mg tablets as well as sustained-release formulations, covering a complete angina management portfolio. The molecule's inclusion in the WHO Essential Medicines List ensures steady demand from institutional buyers in developing countries, and the established API manufacturing base in India keeps production costs competitive. For PCD franchise operators in the cardiac segment, Isosorbide Dinitrate is a foundational product that complements other cardiac therapies and helps build a comprehensive cardiology portfolio for prescribers.